Research about bortezomib-induced thrombocytopenia during relapsed multiple myeloma therapy showed the accumulation of RhoA in megakaryocytes enhanced phosphorylation of myosin light chain and inhibited proplatelet formation [31]. Here, RHOA is linked to plasma cell myeloma.